Real-time enrollment status for this untreated advanced or metastatic gastric, gastroesophageal junction , or esophageal adenocarcinoma clinical trial
Current Status
Recruiting
Checked: October 12, 2026 at 1:03 PM UTC
| NCT Number | NCT07392892 |
| Recruiting Status | Recruiting |
| Condition | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma |
| Phase | PHASE2 |
| Target Enrollment | 840 participants |
| Active Locations | 83 sites in the US |
| Sponsor | Pfizer |
| Last Updated on CT.gov | October 8, 2026 (4 days ago) |
As of October 12, 2026: Clinical trial NCT07392892 is currently recruiting participants. This phase2 study for untreated advanced or metastatic gastric, gastroesophageal junction , or esophageal adenocarcinoma is actively seeking new participants at 83 locations across the United States. The study is sponsored by Pfizer. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07392892 is actively recruiting participants as of October 12, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 83 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07392892 was last updated 4 days ago (October 8, 2026). HelloStudys verifies this status automatically.